COHBAR, INC. (OTCMKTS:CWBR) Files An 8-K Other Events
Item 8.01
On May 3, 2019, CohBar, Inc. issued a press release announcing its plan to resume its Phase 1a/1b clinical trial of CB4211, its lead MBT candidate. A copy of the press release is attached hereto as Exhibit 99.1.
(d) Exhibits
The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:
| 99.1 | CohBar, Inc. press release dated May 3, 2019. |
CohBar, Inc. Exhibit
EX-99.1 2 f8k050319ex99-1_cohbarinc.htm COHBAR,…
To view the full exhibit click here